Background. There is a high drug treatment burden on patients receiving long-term dialysis therapy. Abnormalities of calcium and phosphate metabolism are associated with increased mortality, and attempts to correct these disturbances may improve survival. Methods. We prospectively evaluated the targets of the currently used Kidney Disease: Improving Global Outcomes (KDIGO) guidelines in 8377 prevalent patients receiving intermittent haemodialysis therapy in France from July 2007 to December 2009. Results. Adjusted Cox analyses showed that only one among six targets was predictive of mortality, i.e. a serum intact parathyroid hormone (iPTH) <130 pg/mL. A continuous risk analysis using fractional polynomials showed a 10% increase in hazard ratio (HR) for mortality for a serum phosphate <0.71 (2.2) and >1.98 (6.14) mmol/L (mg/dL), a noncorrected serum calcium <1.59 (6.37) and >2.41 (9.66) mmol/L (mg/dL) and a serum iPTH <100 and >1090 pg/mL. Conclusion. The findings of our observational study confirm the existence of a grey zone, in which precise biochemical targets are difficult to define, with the exception of avoiding extreme values. Given the absence of intervention trials proving the clinical usefulness of phosphorus control, and pending the results of large clinical trials on the effect of optimal PTH and calcium control on hard outcomes, the present findings may help to refine future recommendations for the treatment of chronic haemodialysis patients.
Introduction
The abnormal mineral and bone metabolism developing in association with chronic kidney disease (CKD) results in a systemic disorder now termed as CKD-mineral and bone disorder (CKD-MBD) [1] . The altered bone structure and function and abnormalities of serum phosphate, calcium, parathyroid hormone (PTH) and 25-OH vitamin D in patients with CKD have profound implications for morbidity and quality of life [2, 3] and for the development of extra-skeletal calcifications with an associated increase in the risk of cardiovascular events and mortality [2, [4] [5] [6] [7] [8] . Despite evidence from the Dialysis Outcomes and Practice Patterns Study (DOPPS) indicating that abnormalities in serum concentrations of phosphate, calcium and PTH in the dialysis population have improved in recent years, these abnormalities are far from being corrected in the vast majority of patients with CKD [4, 5, 9, 10] . With dialysis patients being already at increased risk of premature death due to factors such as advanced age [11] , chronic inflammation [12, 13] , anaemia [14] and poor nutritional status [15] , effective management of CKD-MBD has emerged as a clinical priority.
The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines in the USA for bone metabolism and disease in CKD in 2003 [16] focussed and recommended to maintain serum phosphate, calcium and PTH within the narrow ranges, although adherence to the recommended target ranges has proved challenging [1, 2, 17] . Six years later, the international Kidney Disease: Improving Global Outcomes (KDIGO) guideline for CKD-MBD became available, with serum phosphate, calcium and PTH targets being different from those of the KDOQI guidelines. The evidence supporting these two guidelines has, however, been challenged subsequently as it was mainly based on retrospective observational studies. Specifically, the serum calcium, phosphate, 25-OH vitamin D and PTH targets have been questioned for their pertinence to predict morbidity and mortality across time and countries. Unfortunately, given the complete absence of randomised controlled trials assessing the phosphorus control, we can only rely on epidemiological observations. Although numerous publications have addressed this issue in the last 10 years, we sought to add information based on a large and recent prospective cohort of patients, and post-hoc analysed through the KDIGO targets.
The French Phosphate and Calcium Observatory is a large ongoing prospective observational study of clinical and biochemical aspects of mineral and bone metabolism in maintenance dialysis patients. The current analysis evaluates the association between mortality and serum concentrations of phosphate, calcium and PTH in prevalent haemodialysis patients from 2007 to 2009, including patients receiving the recently marketed cinacalcet and lanthanum chloride treatments.
Methods
The French Phosphate and Calcium Observatory is a prospective, multicenter, epidemiological observational study undertaken at 169 dialysis centres in France. All haemodialysis centres in France (∼350) were proposed to enter the study between March and May 2007. The most frequent reason for declining to participate was work overload or competitive clinical studies. Data were collected using an electronic case-report system (Photo-Graph™ software). Investigators completed case-report forms after at least 60 days of maintenance treatment. Data were collected at study entry and then at 6-monthly intervals up to 30 months after entry, i.e. six data collections per patient in total. First enrolment took place in June 2007, with the final data collection in December 2009. Data collected from each region were centralised by regional coordinators to allow the generation of region-specific descriptive analyses. After complete regional data collection, 19 regional files were transferred to the national coordinating centre for final data processing. Data collection was performed with respect to patient's anonymity at the regional and national levels.
All adult patients (>18 years) receiving haemodialysis therapy at participating centres were eligible for inclusion in the study. Patients who had undergone parathyroidectomy in the preceding 6 months were excluded from the analysis. Clinical events, serum biochemistry data and information on patient treatment were collected. At the baseline visit, demographics, dialysis vintage and history of cardiovascular disease were captured. The following data were recorded at each 6-monthly collection point: serum levels of C-reactive protein (CRP), phosphorus, calcium, intact PTH (iPTH) and albumin, normalised protein catabolic rate, history of parathyroidectomy, current medications to control serum phosphate, blood haemoglobin (Hb) concentration, dialysis modality and patient status (on dialysis, dead, lost to follow-up and kidney transplantation). All laboratory evaluations were performed locally. Serum iPTH values were used both as raw values and after adjustment to account for variation in calibration between local PTH assay kits, as described previously [18] . Data were submitted by investigators via a specific casereport software (Photo-Graph™) developed by Genzyme S.A.S, France. All data were anonymised and electronic case-report forms were transmitted by each centre to regional coordinators, who in turn forwarded them to a national coordinator for final data processing. Patients who discontinued the study after the baseline visit were excluded from all survival analyses. Patients who were transplanted or lost to follow-up were included in analyses to the point of study discontinuation.
Statistical analyses were performed using Stata 11™ (Stata Corp, College Station, Texas). Standard descriptive statistics were used to determine mean and standard deviation (SD), or median and 25th and 75th percentile values for demographic, biological and clinical data. Cox regression models were used to calculate hazard ratios (HR) for mortality by month 30 following study entry. Univariate Cox analyses were used to identify covariates for inclusion in the multivariate Cox models, selected if (a) there were at least 30% non-missing values and (b) P < 0.20 on univariate analysis. Gender, age and dialysis vintage were added by default to the model. Potential covariates included body mass index, dialysis vintage, serum albumin and Hb concentrations, systolic and diastolic blood pressure and dialysate calcium concentration (all as continuous variables); use of erythropoiesis stimulating agent therapy, diabetes mellitus, history of cardiovascular disease and use of antihypertensive therapy (all as yes/no variables); smoking history (no/ex-smoker/ yes) and CRP (≤5, >5 to ≤10, >10 to ≤20 or >20 mg/L). The final covariates included in all models were age, gender, body mass index, diabetes and history of cardiovascular disease, dialysis vintage, serum albumin and blood Hb concentrations.
Due to the U shape HR for serum P, Ca and iPTH concentrations, HR higher for low and high concentrations and to avoid the problem of cutpoints and the resulting loss of information [19] , we used fractional polynomials to model these three parameters in the Cox analysis [20] . This technique allows us to model the studied variable using polynomials of degree 1 or 2, where the powers can be fractional and are chosen in the set (−2, −1, −0.5, 0, 0.5, 1, 2, 3). In Stata 11™, the command fracpoly chooses the best fit to calculate the natural logarithm of the HR by selecting one or two parameters in this set and by comparing the result with other choices. In the following example, the 0. 
Results

Patient population
A total of 8377 chronic haemodialysis patients were prospectively enrolled, representing ∼30% of the total haemodialysis patient population in France. Although selected on a voluntary basis, centre selection was representative of the overall population when compared with the national French REIN registry [21, 22] . Nine patients had undergone parathyroidectomy within the preceding 6 months and were excluded, such that the study population comprised 8368 patients. Of these, data on 668 patients were provided only at study entry and they were, therefore, excluded from survival analyses. At the final visit for the remaining 7700 patients, 49.2% (n = 3792) remained on dialysis, 25.9% (n = 1993) had died, 16.8% (n = 1292) had been lost to follow-up and 8.1% (n = 623) had undergone renal transplantation. The mean and median duration of follow-up was 684 and 914 days, respectively. A total of 5339 patients with all values obtained for age, gender, history of cardiovascular disease, diabetes, dialysis vintage, body mass index, serum albumin and Hb concentrations, and serum Pi, Ca and iPTH were included in the Cox analysis. The mean age of the patient population was 67.3 years (59.3% males). They had been receiving intermittent haemodialysis treatment for a median of 3.0 years at study entry. Over half the population (56.8%) had a history of cardiovascular disease. Approximately 80% of the patients were prescribed a phosphate binder, almost half of them active or native vitamin D therapy and approximately one-fifth the calcimimetic cinacalcet ( Table 1) .
Achievement of KDIGO target ranges
The mean serum concentration of phosphate (1.57 ± 0.51 mmol/L) (4.87 ± 0.16 mg/dL) was above the KDIGO recommended values [factually 'normal values of laboratory', e.g. 0.9-1.4 mmol/L (2.8-4.3 mg/dL) for purpose of calculations] ( Table 1 ). The mean serum concentrations of calcium and iPTH were within the recommended ranges for KDIGO guidelines.
Figures 1-3 illustrate the distribution of serum phosphate, total calcium and iPTH among patients at study entry. Only in rare cases did patients have a phosphorus concentration of >2.9 mmol/L (9.0 mg/dL) or a total calcium >2.6 mmol/L (10.42 mg/dL). Table 2 shows the proportion of patients within the recommended KDIGO ranges. They were 32.6% for serum phosphate and 59.4% for uncorrected serum calcium. Almost two over three patients had a serum iPTH concentration within the KDIGO range (>130-585 pg/mL; 60.7%) (uncorrected iPTH values). If iPTH values were corrected based on the Allegro ® kit [18] , the percentage of patients within targets was virtually the same. Approximately 12% of patients were within the KDIGO guideline ranges for all three parameters.
Predictors of all-cause mortality
Among the 7700 prevalent HD patients in whom data were available after study entry, death occurred in 1993 (25.9%). Higher age, history of cardiovascular disease and presence of diabetes were all significantly associated with higher risk of mortality (Table 3) . Longer duration of dialysis was also predictive of mortality, as was an increased serum CRP; indeed, CRP concentrations >20 mg/L conferred the highest relative risk among all factors considered in the present analysis (HR 2.03, 95% CI 1.73-2.38). Markers of protein energy wasting--low body mass index, low serum albumin and low normalised protein catabolic rate [23] --were also significantly associated with an increase in mortality risk. Based on these thresholds, the number of patients 'in target' markedly improved compared with the KDIGO targets: 77% reached the phosphate target, 88% the calcium target and 79% the iPTH target versus 33%, 59% and 62%, respectively. For all the three targets combined, the percentage of patients 'in target' is 55% versus 12% when using the KDIGO values.
The association between baseline mineral metabolism parameters and the 30-month risk of mortality was assessed according to KDIGO recommendations (Table 4) . Low serum iPTH levels according to the lower KDIGO threshold (iPTH ≤ 130 pg/mL) showed a significant association with mortality (HR 1.18, 95% CI 1.04-1.33, P = 0.008), but not high iPTH levels (iPTH > 585 pg/mL).
Continuous HR estimation
We thus performed a Cox regression analysis with fractional polynomials for serum phosphorus (Figure 1 ), calcium ( Figure 2 ) and iPTH ( Figure 3) . The results show that a HR for mortality of 1.10 (i.e. a 10% increased risk above reference) and beyond was observed for serum concentrations of phosphorus <0.71 mmol/L (2.20 mg/dL) and >1.98 mmol/ L (6.14 mg/dL) (Figure 1 ), calcium <1.59 mmol/L (6.37 mg/dL) and >2.41 mmol/L (9.66 mg/dL) ( Figure 2 ) and iPTH <100 pg/mL and >1090 pg/mL ( Figure 3) . We finally performed a Cox regression analysis with fractional polynomials using serum phosphorus, calcium and iPTH as time-varying covariates, from data obtained every 6 months. Interestingly, this analysis led to similar findings. Thus, we do not report this analysis, as it did not provide additional useful information.
Effects of mineral metabolism treatments on survival
We 
Discussion
The French ongoing Phosphate and Calcium Observatory is the most recent and largest European prospective study specifically aimed at assessing disturbances of phosphorus, calcium and PTH metabolism and their relationships with the outcome in dialysis patients. Using the international KDIGO guidelines targets (Table 4) , our findings only confirm the predictive power of only one among the six defined target values, e.g. a low serum iPTH (<130 pg/mL), in this prevalent haemodialysis population over an extended follow-up period of 30 months. Using a more sensitive continuous HR analysis, a HR for mortality of 1.10 was observed for serum concentrations of phosphorus <0.71 mmol/L (95% CI: 0. respectively. By subtracting from analysis the patients with a serum iPTH ≥585 pg/ml (higher KDIGO target, n = 1133), a 10% increase in HR for mortality was observed for a serum phosphorus >2.12 (1.85-2.80) mmol/L [6.57 (5.73-8.68) mg/dL] and was thus even greater than for the whole population. Our analysis also confirms the importance of conventional risk factors and nutritional status as strong predictors of mortality in prevalent haemodialysis patients (Table 3) . To our knowledge, this is the first analysis to assess the KDIGO [24] recommendations for CKD-MBD parameters in terms of their predictive value for mortality risk in a chronic haemodialysis population. In the past, a significant association between the serum phosphorus concentration and the relative risk of mortality in dialysis patients has been consistently demonstrated in observational studies [4, 5, 8, 11, 17, [25] [26] [27] [28] [29] , including a recent meta-analysis [27] . Three of the analyses [4, 8, 27] identified ranges of serum phosphorus, which were associated with the lowest mortality risk, the upper limits of which [1.61 mmol/L (5.0 mg/dL) [5] , 2.1 mmol/L (6.51 mg/dL) [8] and 1.94 mmol/L (6.01 mg/dL) [27] ] were similar or higher than the upper target value of the KDOQI guideline [16] and, specifically, than those of the KDIGO recommendations [24] . Of interest, the current Japanese CKD-MBD guideline has selected an upper limit for serum phosphorus at 1.94 mmol/L (6.01 mg/dL) [29] . This is consistent with our finding that patients with a serum phosphorus of >1.9-2.0 mmol/L (6.1-6.2 mg/dL), but not 1.4 mmol/L (4.34 mg/dL) (KDIGO), were at significantly increased risk of death, although the superimposed risk is relatively modest (Figure 1) .
Neither low nor high serum calcium were predictive of mortality risk based on the KDIGO targets. While a 1998 analysis of the United States Renal Data System (USRDS) data and the above-mentioned meta-analysis [28] found no correlation between serum calcium and relative risk of death, other authors have observed a relationship [4, 5, [25] [26] [27] . A recent examination of DOPPS data showed that a corrected total calcium concentration of less than 2.13 mmol/L or greater than 2.5 mmol/L was associated with a significantly higher all-cause and cardiovascular mortality risk [4] . Elsewhere, a total calcium threshold of ∼2.75 mmol/L for increased mortality risk has been observed [26, 27] . Using a continuous HR analysis (Figure 2) , a significant 10% increase in mortality was observed for a total non-corrected serum calcium concentration above 2.41 mmol/L. This represents the second important finding of our paper and may be the consequence of a more appropriate statistical model we used here. Of note, the KDIGO recommendation for serum calcium was chosen to be the normal laboratory range, based on the absence of valid methodological studies.
As reported in previous large-scale observational studies [4, 5, 8, 26] , a low serum iPTH value was predictive of mortality risk in our population (Figure 3 ). Patients below the lower limit of the KDIGO target range (130 pg/ mL) showed a lower survival. This relationship was steep beneath the 130 pg/mL threshold and statistically robust as the number of patients was large. Accordingly, a recent European analysis of 7970 patients found that serum iPTH values <150 pg/mL were significantly associated with higher mortality risk (HR 1.31) [26] , and similarly the DOPPS analysis by Tentori et al. [4] led to the observation that patients below the 101-300 pg/mL range had an increased relative mortality risk. Here, we did not observe the U-shaped relationship between the iPTH concentration and death reported elsewhere [4, 26] . Indeed, exceeding the upper threshold proposed by KDIGO (585 pg/mL) did not appear to increase the risk of death. Tentori et al. found iPTH levels >600 pg/mL to be significantly predictive of mortality in DOPPS [4] , while the retrospective European analysis by Floege et al. showed a two-fold increase in adjusted risk of death with iPTH >600 pg/mL [26] . Furthermore, by continuous HR analysis, we found a 10% HR increase in values for iPTH <100 pg/mL and >1090 pg/mL, which are confirmative of our KDIGO recommendations analysis ( Table 4 ). The longer follow-up in our population (30 months compared with a median of 21 [4] or 17 months [26] ) could, at least partially, explain the difference observed with these previous publications for elevated iPTH values. Another explanation is that relatively few patients in the present study had serum iPTH values >700 pg/mL, which may render statistical analysis less sensitive in the remote part of the curve (Figure 3) .
In support of the present findings is the prospective collection of data since June 2007, which allows an up-todate analysis. The medication pattern has so much evolved during the last 10 years that the present use of older and retrospective studies may be questionable. Indeed, when compared with many previous analyses, our study takes into account the prescription of recent drugs, such as the calcimimetic cinacalcet and the phosphorus binder lanthanum carbonate, which were not registered until 2005. The estimation of HR for mortality using continuous serum levels of phosphorus, calcium and iPTH may possibly allow a better identification of the risk level associated with these surrogate mineral and bone disease biomarkers. Finally, there is a global 25% reduction of serum phosphorus during the last 15 years [30] , and this may have reduced the therapeutic impact of drugs.
The potential protective effects of vitamin D derivatives and phosphate binders we report here have been already shown previously [31] [32] [33] . However, caution should be advised to use these data to change practice, since our study was not designed to test these hypotheses.
There are limitations to the present study. It is possible that centres enrolled on a voluntary basis were more interested by the correction of CKD-MBD in the care of their haemodialysis patients than those who did not join the study group. However, the baseline characteristics of our patients were not different from those of the global French National Registry (REIN) [22] . Second, the 16.8% patients lost-to-follow-up over 3 years may be a weakness of the present study, although we anticipated a 25% of lost observations in the sample size calculation. In this regard, this number stays within our expectation; however, a ≤10% lost-to-follow-up would have been more advisable. This may partly explain a rather low annual death rate of 10.4% when compared with the French renal registry (REIN) being 16% [34] . If we hypothesise that the ratio death/alive is the same in followed and lost-to-follow-up patients, we should have expected an additional 2.2% annual mortality. This conservative approach raises the annual mortality rate in the present study to ∼12.6%. Third, the present study is only observational and thus hypothesis generating. It should be followed by a well-designed randomised controlled trial aimed at achieving predefined mineral targets by active intervention. Fourth, performing survival analyses using the KDIGO guideline is quite challenging since KDIGO did not recommend precise threshold values, but rather 'normal' laboratory values or, as in the case of iPTH, two to nine times the upper limit value, which may differ from one PTH kit to another.
In conclusion, the findings made in this large-scale, recent prospective cohort of chronic haemodialysis patients confirm for the first time the relative risk of low iPTH values as proposed by the KDIGO recommendations. If we consider a 10% increase risk of mortality, serum phosphate should not exceed 1.98 mmol/L (6.14 mg/dL) and uncorrected serum calcium 2.41 mmol/L (9.66 mg/dL). Patients meeting these targets are thus in greater number, and this may represent 'good news' for both patients and nephrologists making efforts to control mineral metabolism. These findings may be taken into account for the management of MHD patients, in addition to the presence of conventional and nutritional risk factors. The present data may be used in preparing future guidelines.
